Rigel Pharmaceuticals Inc
RIGL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001034842
No open-market purchases or sales by Rigel Pharmaceuticals Inc insiders were filed in the last 90 days; 155 institutions reported holding it in 13F filings for Q2 2026, worth $640.4M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Rigel Pharmaceuticals Inc changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 93 | 122 | +29 |
| Shares | 11.9M | 12.1M | +179.3K (+1.5%) |
| Value | $192.6M | $203.0M | +$10.4M (+5.4%) |
New holders (40)
Institutions that held Rigel Pharmaceuticals Inc at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (11)
Institutions that held Rigel Pharmaceuticals Inc at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Invesco Ltd. | 1,051,355 | $17.0M |
| Stonepine Capital Management, LLC | 309,100 | $5.00M |
| Cubist Systematic Strategies, LLC | 24,264 | $392.6K |
| Price T Rowe Associates Inc | 12,414 | $201.0K |
| Occudo Quantitative Strategies LP | 10,389 | $168.1K |
| National Bank of Canada | 400 | $6.47K |
| Point72 (DIFC) Ltd | 129 | $2.08K |
| Allspring Global Investments Holdings, LLC | 119 | $1.93K |
| Danske Bank A/S | 2 | $32 |
| Capital Performance Advisors LLP | 2 | $32 |
| International Assets Investment Management, LLC | 113 | – |